Anti-tumor activity of tebotelimab in solid tumors
tumor, gastric cancer
GASTRIC CANCER, SECONDARY, SOLID TUMORS, TUMOR
Among 44 patients with advanced solid tumors treated in the dose-escalation phase with single-agent tebotelimab doses ranging from 1 mg to 1,200 mg Q2W and who were evaluable for anti-tumor activity (secondary endpoint), a decreased tumor burden was observed in 11 patients, 10 of whom had received doses above 400 mg. Partial responses (PRs) were seen in three patients: gastric cancer (GC) (